CRISPR Therapeutics publishes presentation on CTX310 Phase 1b trial in severe hypertriglyceridemia
CRSP•CRISPR Therapeutics reported Phase 1b results for CTX310 in 10 participants with severe hypertriglyceridemia. A single infusion reduced triglycerides by a mean 62.8% and ANGPTL3 by 65.3% at 30 days.
1. Phase 1b results
The presentation reported that a single CTX310 infusion reduced triglycerides by a mean 62.8% and ANGPTL3 by 65.3% at 30 days in 10 participants with severe hypertriglyceridemia. No serious adverse events were related to CTX310, and no clinically significant liver enzyme elevations occurred. The results support further development in late-stage trials, while additional Phase 1b cohorts targeting specific lipid disorders are ongoing.
